Pheon Therapeutics, an Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a range of hard-to-treat cancers, announced on Tuesday that it has added Enoch Kariuki, PharmD to its board of directors as an independent, non-executive director.

Dr Kariuki most recently served as CEO of Lengo Therapeutics, which was acquired by Blueprint Medicines. He was previously chief financial officer of VelosBio and senior vice president, Corporate Development at Synthorx. Dr Kariuki was board director and audit chair of Imago Biosciences, which was acquired by Merck, and ProfoundBio, which was acquired by Genmab. He currently serves on the board of Zentalis Pharmaceuticals and is president of Endeavor BioMedicines.

Cyrus Mozayeni, MD, CEO of Pheon, said: "Dr Kariuki joins Pheon at a pivotal stage of growth, as we advance into clinical development with PHN-010, our lead ADC programme targeting patients with advanced solid tumours. His decision to join Pheon's board reflects his belief in our innovative pipeline and our team's track record in targeted oncology therapies and ADCs. Dr Kariuki brings a wealth of executive leadership experience and knowledge in ADCs, which further strengthens our board as we transition into a clinical stage company and beyond."